A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study
NCT ID: NCT05906316
Last Updated: 2025-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2023-07-01
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Mycobacterium Xenopi Pulmonary Infection
NCT01298336
PK and PD of Antibiotics for Treatment of Mycobacterium Abscessus Pulmonary Disease
NCT05676138
Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
NCT00367913
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
NCT00111397
PK and PD of Drugs for Nontuberculous Mycobacterial Diseases in Dutch Patients
NCT01051752
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed and dated informed consent
Exclusion Criteria
* The participant has a known or suspected, current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient
* HIV-infection;
* Cystic fibrosis;
* \>1 month antibiotic treatment for current MAC infection;
* \< 6 months between previous antimycobacterial NTM-PD treatment and antimycobacterial treatment for current MAC-PD
* Disseminated MAC infection;
* Active pulmonary tuberculosis, fungal or nocardial disease requiring treatment;
* Active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 6 months before screening or anticipated during the study period;
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jakko van Ingen, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
Radboud University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon Science and Health University
Portland, Oregon, United States
UZ Leuven
Leuven, , Belgium
University of Calgary
Calgary, Alberta, Canada
University Hospital Center Zagreb
Zagreb, , Croatia
Aarhus University Hospital
Aarhus, , Denmark
Rasmus Rude Laub
Hellerup, , Denmark
University Hospital Frankfurt
Frankfurt, , Germany
Fukujuji Hospital
Tokyo, , Japan
Radboud University Medical Center
Nijmegen, , Netherlands
Seoul National University Hospital
Seoul, , South Korea
Hospital Clínic de Barcelona
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kevin Winthrop, MD, MPH
Role: primary
Mateja Janković Makek, MD, PhD
Role: primary
Role: primary
Nils Wetzstein
Role: primary
Masashi Ito, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-13742
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.